第3项!康方生物PD-1/VEGF双抗新适应症申报上市

医药魔方
25 Jul

7月25日,国家药品监督管理局(NMPA)药品审评中心(CDE)官网显示,康方生物的依沃西单抗新适应症上市申请已获受理。根据其注册性临床研究结果,推测此次申报的适应症为:联合化疗一线治疗晚期鳞状非小细胞肺癌(sq-NSCLC)。依沃西单抗是康方生物自主研发的、全球首创PD-1/VEGF双特异性肿瘤免疫治疗药物。2024年5月,NMPA批准依沃西单抗联合化疗用于治疗经表皮生长因子受体(EGFR)...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10